High affinity humanized anti-CEA monoclonal antibodies
US6333405A · kind A · utility
11Cited by
3References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 28, 2000 |
| Grant date | Dec 25, 2001 |
| Priority date | — |
| Expiry date | Sep 28, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel humanized monoclonal antibodies, fragments or derivatives thereof which specifically bind carcinoembryonic antigen (CEA) are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express CEA as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express CEA.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.